tirzepatide cardiovascular outcomes trial In patients with type 2 diabetes and atherosclerotic disease, was noninferior to dulaglutide with respect to major cardiovascular events. ⁣, ⁣, Read the full SURPASS-CVOT Impact of Body Mass Index,

Eli Lilly has now announced official pricing for orforglipron, sold under the brand name Foundayo and FDA-approved on April 1, 2026

ChenCLuJQuYDongJHongYRenYet al

After joining our weight loss program in Centereach, New York, you can expect to speak to a board-certified physician or provider about your weight loss goals

Maeda N, Jiao H, Kosowska-Chomiczewska IE, Artichowicz W, Preiss U, Szumaa P, et al

Phase 3 data shows 28.7% average weight loss compared to approximately 15% for semaglutide and 20-21% for tirzepatide

Upgrade Your Fresh & Heated Food Merch with Kiosks GLP-1 shoppers spending less doesnt mean they stop buying food